{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:44:26Z","timestamp":1782956666432,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Medical Research, National Taiwan University Hospital","award":["111-CTC0027, 112-CTC0026, 113-CTC0018"],"award-info":[{"award-number":["111-CTC0027, 112-CTC0026, 113-CTC0018"]}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW113-TDU-B-211-114006 and MOHW114-TDU-B-221-144006"],"award-info":[{"award-number":["MOHW113-TDU-B-211-114006 and MOHW114-TDU-B-221-144006"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","award":["partial financial support and product support"],"award-info":[{"award-number":["partial financial support and product support"]}],"id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche","award":["product support"],"award-info":[{"award-number":["product support"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04408-w","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:24:13Z","timestamp":1778307853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Hung-Yang","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Huai","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Che","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Ming","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhe-Cyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"4408_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4408_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H et al (2022) The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology 163:649\u2013658. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.054","journal-title":"Gastroenterology"},{"key":"4408_CR3","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/jco.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K et al (2020) Randomized Phase III KEYNOTE-181 study of Pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38:4138\u20134148. https:\/\/doi.org\/10.1200\/jco.20.01888","journal-title":"J Clin Oncol"},{"key":"4408_CR4","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/s1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506\u20131517. https:\/\/doi.org\/10.1016\/s1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"4408_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/s1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y et al (2020) Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21:832\u2013842. https:\/\/doi.org\/10.1016\/s1470-2045(20)30110-8","journal-title":"Lancet Oncol"},{"key":"4408_CR6","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/jco.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB et al (2022) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized Phase III study. J Clin Oncol 40:3065\u20133076. https:\/\/doi.org\/10.1200\/jco.21.01926","journal-title":"J Clin Oncol"},{"key":"4408_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo HY, Khan KA, Kerbel RS (2024) Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat Rev Clin Oncol 21:468\u2013482. https:\/\/doi.org\/10.1038\/s41571-024-00886-y","journal-title":"Nat Rev Clin Oncol"},{"key":"4408_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15:310\u2013324. https:\/\/doi.org\/10.1038\/nrclinonc.2018.9","journal-title":"Nat Rev Clin Oncol"},{"key":"4408_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, DeRyckere D, Davies KD et al (2014) The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14:769\u2013785. https:\/\/doi.org\/10.1038\/nrc3847","journal-title":"Nat Rev Cancer"},{"key":"4408_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/nejmoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/nejmoa2026982","journal-title":"N Engl J Med"},{"key":"4408_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41591-023-02275-x","volume":"29","author":"NF Saba","year":"2023","unstructured":"Saba NF, Steuer CE, Ekpenyong A et al (2023) Pembrolizumab and Cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 29:880\u2013887. https:\/\/doi.org\/10.1038\/s41591-023-02275-x","journal-title":"Nat Med"},{"key":"4408_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s2468-1253(21)00378-2","volume":"7","author":"X Meng","year":"2022","unstructured":"Meng X, Wu T, Hong Y et al (2022) Camrelizumab plus Apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7:245\u2013253. https:\/\/doi.org\/10.1016\/s2468-1253(21)00378-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4408_CR13","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/jco.21.00939","volume":"39","author":"SK Pal","year":"2021","unstructured":"Pal SK, McGregor B, Su\u00e1rez C et al (2021) Cabozantinib in combination with Atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J Clin Oncol 39:3725\u20133736. https:\/\/doi.org\/10.1200\/jco.21.00939","journal-title":"J Clin Oncol"},{"key":"4408_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/s1470-2045(22)00278-9","volume":"23","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, McGregor B, Maughan BL et al (2022) Cabozantinib in combination with Atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol 23:899\u2013909. https:\/\/doi.org\/10.1016\/s1470-2045(22)00278-9","journal-title":"Lancet Oncol"},{"key":"4408_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","volume":"5","author":"MA Shah","year":"2019","unstructured":"Shah MA, Kojima T, Hochhauser D et al (2019) Efficacy and safety of Pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol 5:546\u2013550. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5441","journal-title":"JAMA Oncol"},{"key":"4408_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03826-y","volume":"73","author":"JC Guo","year":"2024","unstructured":"Guo JC, Huang TC, Kuo HY et al (2024) Adjuvant chemoradiotherapy plus Pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study. Cancer Immunol Immunother 73:230. https:\/\/doi.org\/10.1007\/s00262-024-03826-y","journal-title":"Cancer Immunol Immunother"},{"key":"4408_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/s0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"4408_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/nejmoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386:449\u2013462. https:\/\/doi.org\/10.1056\/nejmoa2111380","journal-title":"N Engl J Med"},{"key":"4408_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/s1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E et al (2023) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 24:483\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(23)00108-0","journal-title":"Lancet Oncol"},{"key":"4408_CR20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1158\/1078-0432.ccr-24-4123","volume":"31","author":"I Tseng","year":"2025","unstructured":"Tseng I, Chen Y, Ai D et al (2025) Radiation dose-volume effects on negative tumor-draining lymph nodes impacted T-cell activation and prognosis in esophageal cancer with chemoradiotherapy. Clin Cancer Res 31:2024\u20132033. https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-4123","journal-title":"Clin Cancer Res"},{"key":"4408_CR21","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.21873\/anticanres.13765","volume":"39","author":"JC Guo","year":"2019","unstructured":"Guo JC, Lin CC, Lin CY et al (2019) Neutrophil-to-lymphocyte ratio and use of antibiotics associated with prognosis in esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitors. Anticancer Res 39:5675\u20135682. https:\/\/doi.org\/10.21873\/anticanres.13765","journal-title":"Anticancer Res"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"11115","DOI":"10.1073\/pnas.1406259111","volume":"111","author":"M Giordano","year":"2014","unstructured":"Giordano M, Roncagalli R, Bourdely P et al (2014) The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci U S A 111:11115\u201311120. https:\/\/doi.org\/10.1073\/pnas.1406259111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4408_CR23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A","volume":"30","author":"A Joss","year":"2000","unstructured":"Joss A, Akdis M, Faith A, Blaser K, Akdis CA (2000) IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 30:1683\u20131690. https:\/\/doi.org\/10.1002\/1521-4141(200006)30:6%3c1683::AID-IMMU1683%3e3.0.CO;2-A","journal-title":"Eur J Immunol"},{"key":"4408_CR24","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.4049\/jimmunol.1202775","volume":"190","author":"HW Chen","year":"2013","unstructured":"Chen HW, Chen HY, Wang LT et al (2013) Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 190:5065\u20135077. https:\/\/doi.org\/10.4049\/jimmunol.1202775","journal-title":"J Immunol"},{"key":"4408_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41423-024-01199-x","volume":"21","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen W, Qiao S et al (2024) Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20\/CCR6 axis in human hepatocellular carcinoma. Cell Mol Immunol 21:1120\u20131130. https:\/\/doi.org\/10.1038\/s41423-024-01199-x","journal-title":"Cell Mol Immunol"},{"key":"4408_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajpath.2024.09.011","volume":"195","author":"L Huang","year":"2025","unstructured":"Huang L, Yang J, Zhu J et al (2025) Programmed Death Ligand-1 in melanoma and extracellular vesicles promotes local and regional immune suppression through M2-like macrophage polarization. Am J Pathol 195:306\u2013320. https:\/\/doi.org\/10.1016\/j.ajpath.2024.09.011","journal-title":"Am J Pathol"},{"key":"4408_CR27","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3892\/ol.2017.6614","volume":"14","author":"Y Qi","year":"2017","unstructured":"Qi Y, Cao KX, Xing FC et al (2017) High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma. Oncol Lett 14:3415\u20133420. https:\/\/doi.org\/10.3892\/ol.2017.6614","journal-title":"Oncol Lett"},{"key":"4408_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jfma.2019.10.010","volume":"119","author":"HY Kuo","year":"2020","unstructured":"Kuo HY, Guo JC, Hsu CH (2020) Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: a long-awaited breakthrough finally arrives. J Formos Med Assoc 119:565\u2013568. https:\/\/doi.org\/10.1016\/j.jfma.2019.10.010","journal-title":"J Formos Med Assoc"},{"key":"4408_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114328","volume":"212","author":"X Meng","year":"2024","unstructured":"Meng X, Wang J, Xia J et al (2024) Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study. Eur J Cancer 212:114328. https:\/\/doi.org\/10.1016\/j.ejca.2024.114328","journal-title":"Eur J Cancer"},{"key":"4408_CR30","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2217\/fon-2022-1148","volume":"20","author":"JM Sun","year":"2024","unstructured":"Sun JM, Adenis A, Enzinger CP et al (2024) LEAP-014: First-line lenvatinib + pembrolizumab + chemotherapy in advanced\/metastatic esophageal squamous cell carcinoma. Future Oncol 20:2709\u20132721. https:\/\/doi.org\/10.2217\/fon-2022-1148","journal-title":"Future Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04408-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:50:30Z","timestamp":1782953430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04408-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Guo: Financial Interests, Personal, Invited Speaker, Travel grant: Ipsen; Financial Interests, Personal, Invited Speaker: Roche. C. Lin: Financial Interests, Personal, Advisory Role: AbbVie, Anbogen, Blueprint Medicines, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, IMPACT, Merck KGaA, Novartis, Pharma Engines, Pfizer; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, Eli-Lilly, Novartis, Roche; Financial Interests, Personal, Other, Travel support for attending meetings: BeiGene, Daiichi Sankyo, Eli Lilly, IMPACT. T. Wu: Financial Interests, Personal, Invited Speaker: Roche. C. Hsu: Financial Interests, Institutional, Research Grant: BeiGene, Gilead, Ipsen, Ono Pharmaceutical, and F. Hoffmann-La Roche Ltd; Financial Interests, Personal and Institutional, Principal Investigator, sponsor-initiated clinical trials: AstraZeneca, BeiGene, Bristol Myers Squibb, Merck Sharp & Dohme, Ono Pharmaceutical, F. Hoffmann-La Roche Ltd, NGM Biopharmaceuticals, Pfizer, and Surface Oncology; Financial Interests, Personal, Advisory Role: AstraZeneca, BeiGene, Ono Pharmaceutical, and F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Invited Speaker: BMS, Daiichi Sankyo, Eisai, Merck Sharp & Dohme, Ono Pharmaceutical, and F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Other, support for attending meetings and\/or travel: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Board: Daiichi Sankyo and F. Hoffmann-La Roche Ltd. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the research ethics committee of our institute (approval number: 202101041MIPB). The study was conducted in accordance with the Declaration of Helsinki and ICH guidelines for Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients prior to inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"176"}}